Open Access

Validity of an NGS‑based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital

  • Authors:
    • Wei Cao
    • Chenghai Yan
    • Hailong Wang
    • Tom Tang
    • Haifeng Wang
    • Dujuan Liu
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/ol.2019.10265
  • Pages: 5425-5434
  • Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer. A number of targeted therapies have been approved for clinical use or are in clinical trials. Next generation sequencing (NGS) is widely applied in the identification of actionable genomic alterations and enables personalized cancer therapy for patients. Several multiple‑gene panels are available in China for the practice of precision medicine‑based cancer therapy. However, the efficiency of these panels requires evaluation. The current study investigated 23 NSCLC samples using a custom designed panel of complete coding regions of ~180 cancer driver genes (FD‑180) and whole exome sequencing for control samples, obtained from white blood cell samples. The results obtained suggested that actionable mutations with available targeted therapeutic options were identified in 69.6% of cases, including 60.9% of therapeutic targets recommended by the National Comprehensive Cancer Network guidelines. Furthermore, 8.7% of patients had a gene mutation that potentially qualified them for clinical trials or associated off‑label therapies. As such, the results obtained in the current study demonstrated the reliability of the targeted NGS panel and its potential use for identifying actionable gene alterations and designing personalized therapies for patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

June-2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Cao, W., Yan, C., Wang, H., Tang, T., Wang, H., & Liu, D. (2019). Validity of an NGS‑based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital. Oncology Letters, 17, 5425-5434. https://doi.org/10.3892/ol.2019.10265
MLA
Cao, W., Yan, C., Wang, H., Tang, T., Wang, H., Liu, D."Validity of an NGS‑based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital". Oncology Letters 17.6 (2019): 5425-5434.
Chicago
Cao, W., Yan, C., Wang, H., Tang, T., Wang, H., Liu, D."Validity of an NGS‑based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital". Oncology Letters 17, no. 6 (2019): 5425-5434. https://doi.org/10.3892/ol.2019.10265